A lack of funding threatens to deny Australians access to a promising new cancer immunotherapy which is already achieving success in the clinic.
QIMR Berghofer is appealing for the community to support Dr Siok Tey’s cutting-edge CAR T cell therapy research which has achieved remission for some lymphoma patients and holds great promise against the aggressive blood cancer, myeloma, and some solid cancers including those affecting children.
CAR T cell therapy is a beacon of hope for blood cancer patients who have run out of treatment options, but funding is urgently needed to progress the research and make the treatment accessible for Australians who need it.
The public is urged to donate to the annual QIMR Berghofer tax appeal and make a real difference to local cancer patients and their families.